GPX4 and neoplasm: However, in older patients the altered systemic iron/copper milieu and increased burden of senescent cells may change the therapeutic window: increased tissue iron could enhance tumor killing but also raise risks of collateral tissue ferroptosis and necroinflammation, while copper modulation could impair antioxidant defenses (GPX4/GSH) in non-tumor tissues [34,104].